Gene Biotherapeutics (Gene Biotherapeutics) FCF Margin % : 0.00% (As of Dec. 2020)

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Gene Biotherapeutics's Free Cash Flow for the three months ended in Dec. 2020 was $-0.34 Mil. Gene Biotherapeutics's Revenue for the three months ended in Dec. 2020 was $0.00 Mil. Therefore, Gene Biotherapeutics's FCF Margin % for the quarter that ended in Dec. 2020 was 0.00%.

As of today, Gene Biotherapeutics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Gene Biotherapeutics's FCF Margin % or its related term are showing as below:

CRXM's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -137.43
* Ranked among companies with meaningful FCF Margin % only.

Gene Biotherapeutics FCF Margin % Historical Data

The historical data trend for Gene Biotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics FCF Margin % Chart

Gene Biotherapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

FCF Margin %

Get a 7-Day Free Trial

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Gene Biotherapeutics's FCF Margin %

For the Biotechnology subindustry, Gene Biotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gene Biotherapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's FCF Margin % falls into.

Gene Biotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Gene Biotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2020 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2020 )	/	Revenue (A: Dec. 2020 )
	=	-1.136	/	0
	=	%

Gene Biotherapeutics's FCF Margin for the quarter that ended in Dec. 2020 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2020 )	/	Revenue (Q: Dec. 2020 )
	=	-0.338	/	0
	=	%

Gene Biotherapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010